Evolving Treatment in Newly Diagnosed Multiple Myeloma Patients - Episode 3

Impact of Clinical Trials on the Treatment Landscape for TIE NDMM and Decision-Making Between Triplet vs Quadruplet Therapy

November 20, 2024

Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute

Elizabeth O’Donnell, MD, comments on how the aforementioned trials have influenced the treatment landscape for transplant-ineligible patients with newly diagnosed multiple myeloma and discusses situations in which she favors triplet therapy over quadruplet therapy for these patients.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Key Considerations and Patient Factors in Frontline Therapy Selection for Transplant-Ineligible NDMM Patients

EP. 2: Brief Overview of MAIA, IMROZ, BENEFIT, and CEPHEUS Clinical Trials

Now Viewing

EP. 3: Impact of Clinical Trials on the Treatment Landscape for TIE NDMM and Decision-Making Between Triplet vs Quadruplet Therapy

EP. 4: Optimizing Regimens and Managing Adverse Events in TIE NDMM

EP. 5: Looking Ahead and Key Takeaways

EP. 6: Current Treatment Landscape of Newly Diagnosed Multiple Myeloma Patients

EP. 7: Overview of PERSEUS, IsKia, and GMMG-HD7

EP. 8: Clinical Factors for Transplant Eligibility and Treatment Strategy in NDMM

Please comment on how the above trials influenced the treatment landscape for transplant-ineligible (TIE) patients with newly diagnosed multiple myeloma.
Please comment on situations in which you favor triplet therapy over quadruplet therapy for TIE patients.